{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:38:39Z","timestamp":1788514719337,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG052560"],"award-info":[{"award-number":["R01AG052560"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG052560"],"award-info":[{"award-number":["R01AG052560"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K23AG057794"],"award-info":[{"award-number":["K23AG057794"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The pathological effects of amyloid \u03b2 oligomers (A\u03b2o) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimer\u2019s disease (AD). Positron emission tomography (PET) studies of mGluR5 using [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPEB indicate a reduction of receptor binding that is focused in the medial temporal lobe in AD. Synaptic loss due to AD measured through synaptic vesicle glycoprotein 2A (SV2A) quantification with [\n                      <jats:sup>11<\/jats:sup>\n                      C]UCB-J PET is also focused in the medial temporal lobe, but with clear widespread reductions is commonly AD-affected neocortical regions. In this study, we used [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPEB and [\n                      <jats:sup>11<\/jats:sup>\n                      C]UCB-J PET to investigate the relationship between mGluR5 and synaptic density in early AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fifteen amyloid positive participants with early AD and 12 amyloid negative, cognitively normal (CN) participants underwent PET scans with both [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPEB to measure mGluR5 and [\n                      <jats:sup>11<\/jats:sup>\n                      C]UCB-J to measure synaptic density. Parametric distribution volume ratio (\n                      <jats:italic>DVR)<\/jats:italic>\n                      images using equilibrium methods were generated from dynamic images. For [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPEB PET,\n                      <jats:italic>DVR<\/jats:italic>\n                      was calculated using equilibrium methods and a cerebellum reference region. For [\n                      <jats:sup>11<\/jats:sup>\n                      C]UCB-J PET,\n                      <jats:italic>DVR<\/jats:italic>\n                      was calculated with a simplified reference tissue model \u2013 2 and a whole cerebellum reference region.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A strong positive correlation between mGluR5 and synaptic density was present in the hippocampus for participants with AD (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and in the CN group (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). In the entorhinal cortex, there was a strong positive correlation between mGluR5 and synaptic density in the AD group (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but a weaker non-significant correlation in the CN group (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.36,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.245). Exploratory analyses indicated more widespread significant positive correlations between synaptic density and mGluR5 within regions, as well as significant positive correlations between synaptic density in the temporal lobe and mGluR5 across a broader set of regions commonly affected by AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that mGluR5 reduction in AD is closely linked to synaptic loss. Longitudinal studies are needed to clarify causality, deepen understanding of AD pathogenesis, and aid in developing novel biomarkers and treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01739-1","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T02:37:24Z","timestamp":1746499044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of the relationship between synaptic density and metabotropic glutamate receptors in early Alzheimer\u2019s disease: a multi-tracer PET study"],"prefix":"10.1186","volume":"17","author":[{"given":"Elaheh","family":"Salardini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em","family":"Tchorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel B.","family":"Nabulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"van Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Mecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"1","key":"1739_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0197-4580(90)90059-9","volume":"11","author":"SW Scheff","year":"1990","unstructured":"Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer\u2019s disease. Neurobiol Aging. 1990;11(1):29\u201337.","journal-title":"Neurobiol Aging"},{"issue":"5594","key":"1739_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298(5594):789\u201391.","journal-title":"Science"},{"issue":"4","key":"1739_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1006\/neur.1996.0056","volume":"5","author":"ST DeKosky","year":"1996","unstructured":"DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996;5(4):417\u201321.","journal-title":"Neurodegeneration"},{"issue":"3","key":"1739_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1212\/WNL.39.3.355","volume":"39","author":"JE Hamos","year":"1989","unstructured":"Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer\u2019s disease and other dementias. Neurology. 1989;39(3):355\u201361.","journal-title":"Neurology"},{"issue":"5","key":"1739_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"4","key":"1739_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"7","key":"1739_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, Chen MK, O\u2019Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimers Dement. 2020;16(7):974\u201382.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1739_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0304-3940(94)90121-X","volume":"174","author":"E Masliah","year":"1994","unstructured":"Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer\u2019s disease. Neurosci Lett. 1994;174(1):67\u201372.","journal-title":"Neurosci Lett"},{"issue":"10","key":"1739_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","volume":"27","author":"SW Scheff","year":"2006","unstructured":"Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372\u201384.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"1739_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JAD-141518","volume":"43","author":"SW Scheff","year":"2015","unstructured":"Scheff SW, Price DA, Ansari MA, Roberts KN, Schmitt FA, Ikonomovic MD, et al. Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer\u2019s disease. J Alzheimers Dis. 2015;43(3):1073\u201390.","journal-title":"J Alzheimers Dis"},{"issue":"348","key":"1739_CR11","doi-asserted-by":"publisher","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra96.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1739_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2967\/jnumed.115.168179","volume":"57","author":"NB Nabulsi","year":"2016","unstructured":"Nabulsi NB, Mercier J, Holden D, Carr\u00e9 S, Najafzadeh S, Vandergeten MC, et al. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. J Nucl Med. 2016;57(5):777\u201384.","journal-title":"J Nucl Med"},{"issue":"10","key":"1739_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"MK Chen","year":"2018","unstructured":"Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, et al. Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75(10):1215\u201324.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1739_CR14","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994","volume":"14","author":"SM Bajjalieh","year":"1994","unstructured":"Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223\u201335.","journal-title":"J Neurosci"},{"issue":"6","key":"1739_CR15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1073\/pnas.90.6.2150","volume":"90","author":"SM Bajjalieh","year":"1993","unstructured":"Bajjalieh SM, Peterson K, Linial M, Scheller RH. Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A. 1993;90(6):2150\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1739_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13195-020-00742-y","volume":"13","author":"RS O'Dell","year":"2021","unstructured":"O\u2019Dell RS, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, et al. Association of A\u03b2 deposition and regional synaptic density in early Alzheimer\u2019s disease: a PET imaging study with [(11)C]UCB-J. Alzheimers Res Ther. 2021;13(1):11.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1739_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/0271678X231153730","volume":"43","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang J, Xu X, You Z, Huang Q, Huang Y, et al. In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2023;43(6):977\u201388.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"1739_CR18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1177\/0271678X241230733","volume":"44","author":"J Li","year":"2024","unstructured":"Li J, Huang Q, Qi N, He K, Li S, Huang L, et al. The associations between synaptic density and \u201cA\/T\/N\u201d biomarkers in Alzheimer\u2019s disease: An (18)F-SynVesT-1 PET\/MR study. J Cereb Blood Flow Metab. 2024;44(7):1199\u2013207.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"1739_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47(2):390\u2013402.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1739_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-021-00772-0","volume":"13","author":"EM Coomans","year":"2021","unstructured":"Coomans EM, Schoonhoven DN, Tuncel H, Verfaillie SCJ, Wolters EE, Boellaard R, et al. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimers Res Ther. 2021;13(1):35.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1739_CR21","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1212\/WNL.0000000000009818","volume":"95","author":"H Vanhaute","year":"2020","unstructured":"Vanhaute H, Ceccarini J, Michiels L, Koole M, Sunaert S, Lemmens R, et al. In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology. 2020;95(5):e545\u201353.","journal-title":"Neurology"},{"issue":"10","key":"1739_CR22","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1038\/s41380-022-01672-x","volume":"27","author":"G Vanderlinden","year":"2022","unstructured":"Vanderlinden G, Ceccarini J, Vande Casteele T, Michiels L, Lemmens R, Triau E, et al. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Mol Psychiatry. 2022;27(10):4244\u201351.","journal-title":"Mol Psychiatry"},{"key":"1739_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fphar.2012.00199","volume":"3","author":"TM Piers","year":"2012","unstructured":"Piers TM, Kim DH, Kim BC, Regan P, Whitcomb DJ, Cho K. Translational concepts of mglur5 in synaptic diseases of the brain. Front Pharmacol. 2012;3:199.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1739_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12035-011-8187-z","volume":"44","author":"KE Cosgrove","year":"2011","unstructured":"Cosgrove KE, Galv\u00e1n EJ, Barrionuevo G, Meriney SD. mGluRs modulate strength and timing of excitatory transmission in hippocampal area CA3. Mol Neurobiol. 2011;44(1):93\u2013101.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1739_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-020-0582-0","volume":"12","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, et al. PET imaging of mGluR5 in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):15.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"1739_CR26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/j.1460-9568.1996.tb01611.x","volume":"8","author":"R Lujan","year":"1996","unstructured":"Lujan R, Nusser Z, Roberts JD, Shigemoto R, Somogyi P. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci. 1996;8(7):1488\u2013500.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"1739_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41467-022-35680-w","volume":"14","author":"N Scheefhals","year":"2023","unstructured":"Scheefhals N, Westra M, MacGillavry HD. mGluR5 is transiently confined in perisynaptic nanodomains to shape synaptic function. Nat Commun. 2023;14(1):244.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"1739_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0006-8993(96)00697-X","volume":"736","author":"I Bl\u00fcmcke","year":"1996","unstructured":"Bl\u00fcmcke I, Behle K, Malitschek B, Kuhn R, Kn\u00f6pfel T, Wolf HK, et al. Immunohistochemical distribution of metabotropic glutamate receptor subtypes mGluR1b, mGluR2\/3, mGluR4a and mGluR5 in human hippocampus. Brain Res. 1996;736(1\u20132):217\u201326.","journal-title":"Brain Res"},{"issue":"19","key":"1739_CR29","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","volume":"17","author":"R Shigemoto","year":"1997","unstructured":"Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci. 1997;17(19):7503\u201322.","journal-title":"J Neurosci"},{"issue":"1","key":"1739_CR30","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1038\/s41598-018-22768-x","volume":"8","author":"KJ O'Riordan","year":"2018","unstructured":"O\u2019Riordan KJ, Hu NW, Rowan MJ. Physiological activation of mGlu5 receptors supports the ion channel function of NMDA receptors in hippocampal LTD induction in vivo. Sci Rep. 2018;8(1):4391.","journal-title":"Sci Rep"},{"issue":"1","key":"1739_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00213-020-05661-2","volume":"238","author":"ST Yang","year":"2021","unstructured":"Yang ST, Wang M, Galvin V, Yang Y, Arnsten AFT. Effects of blocking mGluR5 on primate dorsolateral prefrontal cortical neuronal firing and working memory performance. Psychopharmacology. 2021;238(1):97\u2013106.","journal-title":"Psychopharmacology"},{"issue":"5","key":"1739_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neuron.2010.04.029","volume":"66","author":"M Renner","year":"2010","unstructured":"Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010;66(5):739\u201354.","journal-title":"Neuron"},{"issue":"5","key":"1739_CR33","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","volume":"79","author":"JW Um","year":"2013","unstructured":"Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u03b2 oligomer bound to cellular prion protein. Neuron. 2013;79(5):887\u2013902.","journal-title":"Neuron"},{"issue":"Pt 2","key":"1739_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/brain\/awv356","volume":"139","author":"LT Haas","year":"2016","unstructured":"Haas LT, Salazar SV, Kostylev MA, Um JW, Kaufman AC, Strittmatter SM. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer\u2019s disease. Brain. 2016;139(Pt 2):526\u201346.","journal-title":"Brain"},{"issue":"47","key":"1739_CR35","doi-asserted-by":"publisher","first-page":"16857","DOI":"10.1523\/JNEUROSCI.1858-12.2012","volume":"32","author":"M Larson","year":"2012","unstructured":"Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, et al. The complex PrP(c)-Fyn couples human oligomeric A\u03b2 with pathological tau changes in Alzheimer\u2019s disease. J Neurosci. 2012;32(47):16857\u201371.","journal-title":"J Neurosci"},{"issue":"647","key":"1739_CR36","doi-asserted-by":"publisher","first-page":"eabi8593","DOI":"10.1126\/scitranslmed.abi8593","volume":"14","author":"J Spurrier","year":"2022","unstructured":"Spurrier J, Nicholson L, Fang XT, Stoner AJ, Toyonaga T, Holden D, et al. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med. 2022;14(647):eabi8593.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1739_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","volume":"20","author":"LT Haas","year":"2017","unstructured":"Haas LT, Salazar SV, Smith LM, Zhao HR, Cox TO, Herber CS, et al. Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes. Cell Rep. 2017;20(1):76\u201388.","journal-title":"Cell Rep"},{"issue":"9","key":"1739_CR38","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.celrep.2016.04.077","volume":"15","author":"A Hamilton","year":"2016","unstructured":"Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS. Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an alzheimer disease mouse model. Cell Rep. 2016;15(9):1859\u201365.","journal-title":"Cell Rep"},{"key":"1739_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107785","volume":"160","author":"PMQ Bellozi","year":"2019","unstructured":"Bellozi PMQ, Gomes GF, da Silva MCM, Lima IVA, Batista C, Carneiro Junior WO, et al. A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer\u2019s disease. Neuropharmacology. 2019;160: 107785.","journal-title":"Neuropharmacology"},{"key":"1739_CR40","unstructured":"Mecca AP, Salardini E, Gallezot JD, O\u2019dell RS, Young J, Cooper E, et al. A phase 1a single ascending dose study of the safety, tolerability, and brain receptor occupancy of BMS984923 in healthy older adults. Clinical Trials on Alzheimer\u2019s Disease. 2023; Boston, MA-USA 2023."},{"key":"1739_CR41","unstructured":"Evaluating the safety, tolerability, pharmacokinetics and receptor occupancy of BMS-984923 [NCT04805983]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04805983?term=NCT04805983&rank=1."},{"key":"1739_CR42","unstructured":"Food effect study of BMS-984923 in healthy older adult volunteers [NCT05817643]. Available from: https:\/\/clinicaltrials.gov\/search?term=NCT05817643."},{"issue":"6","key":"1739_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1632","volume":"10","author":"V Treyer","year":"2020","unstructured":"Treyer V, Gietl AF, Suliman H, Gruber E, Meyer R, Buchmann A, et al. Reduced uptake of [11C]-ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer\u2019s dementia. Brain Behav. 2020;10(6): e01632.","journal-title":"Brain Behav"},{"issue":"1","key":"1739_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-024-01385-z","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang J, He Y, Chen X, Huang L, Li J, You Z, et al. Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer\u2019s disease: A [(18)F]PSS232 PET\/MRI study. Alzheimers Res Ther. 2024;16(1):9.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"1739_CR45","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/alz.12582","volume":"18","author":"AP Mecca","year":"2022","unstructured":"Mecca AP, O\u2019Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, et al. Synaptic density and cognitive performance in Alzheimer\u2019s disease: A PET imaging study with [(11) C]UCB-J. Alzheimers Dement. 2022;18(12):2527\u201336.","journal-title":"Alzheimers Dement"},{"issue":"16","key":"1739_CR46","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1739_CR47","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774\u201381.","journal-title":"Neuroimage"},{"issue":"5","key":"1739_CR48","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1088\/0031-9155\/52\/5\/019","volume":"52","author":"HW de Jong","year":"2007","unstructured":"de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52(5):1505\u201326.","journal-title":"Phys Med Biol"},{"key":"1739_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2017.09.027","volume":"61","author":"AP Mecca","year":"2018","unstructured":"Mecca AP, Barcelos NM, Wang S, Br\u00fcck A, Nabulsi N, Planeta-Wilson B, et al. Cortical \u03b2-amyloid burden, gray matter, and memory in adults at varying APOE \u03b54 risk for Alzheimer\u2019s disease. Neurobiol Aging. 2018;61:207\u201314.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"1739_CR50","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/0271678X17724947","volume":"38","author":"SJ Finnema","year":"2018","unstructured":"Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, et al. Kinetic evaluation and test-retest reproducibility of [(11)C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cereb Blood Flow Metab. 2018;38(11):2041\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"1739_CR51","doi-asserted-by":"publisher","DOI":"10.1118\/1.4819820","volume":"40","author":"X Jin","year":"2013","unstructured":"Jin X, Mulnix T, Gallezot JD, Carson RE. Evaluation of motion correction methods in human brain PET imaging\u2013a simulation study based on human motion data. Med Phys. 2013;40(10): 102503.","journal-title":"Med Phys"},{"key":"1739_CR52","doi-asserted-by":"crossref","unstructured":"Carson R, Barker C, Liow J-S, Johnson C. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. In: IEEE Nuclear Science Symposium. Portland; 2003. p. 3281\u20135.","DOI":"10.1109\/NSSMIC.2003.1352597"},{"issue":"21","key":"1739_CR53","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1088\/0031-9155\/57\/21\/R119","volume":"57","author":"K Erlandsson","year":"2012","unstructured":"Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57(21):R119\u201359.","journal-title":"Phys Med Biol"},{"issue":"7","key":"1739_CR54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12149-017-1185-0","volume":"31","author":"M Shidahara","year":"2017","unstructured":"Shidahara M, Thomas BA, Okamura N, Ibaraki M, Matsubara K, Oyama S, et al. A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [(18)F]THK5351 and [(11)C]PIB. Ann Nucl Med. 2017;31(7):563\u20139.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1739_CR55","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/01.WCB.0000033967.83623.34","volume":"22","author":"Y Wu","year":"2002","unstructured":"Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22(12):1440\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"1739_CR56","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s00259-023-06487-8","volume":"51","author":"T Toyonaga","year":"2024","unstructured":"Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot JD, et al. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [(11)C]UCB-J. Eur J Nucl Med Mol Imaging. 2024;51(4):1012\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1739_CR57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2967\/jnumed.119.228080","volume":"61","author":"A Mansur","year":"2020","unstructured":"Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M, et al. Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: (18)F-BCPP-EF, (11)C-SA-4503, and (11)C-UCB-J. J Nucl Med. 2020;61(1):96\u2013103.","journal-title":"J Nucl Med"},{"key":"1739_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.117877","volume":"232","author":"L Michiels","year":"2021","unstructured":"Michiels L, Delva A, van Aalst J, Ceccarini J, Vandenberghe W, Vandenbulcke M, et al. Synaptic density in healthy human aging is not influenced by age or sex: a (11)C-UCB-J PET study. Neuroimage. 2021;232: 117877.","journal-title":"Neuroimage"},{"key":"1739_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118217","volume":"238","author":"AP Mecca","year":"2021","unstructured":"Mecca AP, Rogers K, Jacobs Z, McDonald JW, Michalak HR, DellaGioia N, et al. Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [(18)F]FPEB PET. Neuroimage. 2021;238: 118217.","journal-title":"Neuroimage"},{"issue":"2","key":"1739_CR60","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awx347","volume":"141","author":"TE Cope","year":"2018","unstructured":"Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the functional connectome in Alzheimer\u2019s disease and progressive supranuclear palsy. Brain. 2018;141(2):550\u201367.","journal-title":"Brain"},{"issue":"6","key":"1739_CR61","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1002\/alz.13817","volume":"20","author":"J Wang","year":"2024","unstructured":"Wang J, Huang Q, He K, Li J, Guo T, Yang Y, et al. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment. Alzheimers Dement. 2024;20(6):3876\u201388.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01739-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01739-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01739-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:02:41Z","timestamp":1746504161000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01739-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01739-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.21.614277","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Yale University Human Investigation Committee and Radiation Safety Committee. All participants provided written informed consent prior to participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.P.M., R.E.C., and C.H.vD. report grants from the National Institutes of Health for the conduct of the study. A.P.M. reports grants for clinical trials from Eli Lilly and Janssen Pharmaceuticals outside the submitted work. Y.H. reports research grants from UCB and Eli Lilly outside the submitted work. Y.H., N.B.N., and R.E.C. have a patent for a newer version of the tracer. R.E.C. is a consultant for Rodin Therapeutics and has received research funding from UCB. R.E.C. reports having received grants from AstraZeneca, Astellas, Eli Lilly, Pfizer, Taisho, and UCB outside the submitted work. C.H.vD. reports consulting fees from Kyowa Kirin, Roche, Merck, Eli Lilly, and Janssen and grants for clinical trials from Biogen, Novartis, Eli Lilly, Merck, Eisai, Janssen, Roche, Genentech, Toyama, and Biohaven outside the submitted work. R.S.O. reports grants for clinical trials from Cognition Therapeutics and Bristol-Myers Squibb outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}